Drug intelligence / Profile preview

CAM-6019

Development stage: Preclinical
Lead developer: Cambrian Bio

Overview

CAM-6019 is a preclinical-stage drug candidate being developed by Cambrian Bio (within one of its stealth-mode subsidiary companies) for the treatment of cardiovascular diseases. As of the current pipeline disclosures, the specific molecular target, mechanism of action, and therapeutic modality remain proprietary and have not been publicly released. The program is part of Cambrian Bio's broader portfolio aimed at developing 'Geroscience' medicines that target the biological drivers of aging to treat and prevent chronic diseases.

Targets

α-DG (Alpha-dystroglycan)NeuraminidaseEPCR (Endothelial protein C receptor)

Beyond the preview

Go deeper on CAM-6019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAM-6019.

Explore the full profile